Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Factors of Influence in 2018, Key Indicators and Opportunity within PPL, The Travelers Companies, Xilinx, United Bankshares, DaVita, and OncoSec Medical -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PPL Corporation (NYSE:PPL),...

UBSI : 38.40 (+0.66%)
XLNX : 67.68 (-1.40%)
TRV : 123.45 (-1.23%)
ONCS : 1.38 (-3.50%)
PPL : 27.84 (+1.94%)
DVA : 72.08 (-0.50%)
OncoSec Presents Update on PISCES/KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial in Combination with Merck's KEYTRUDA® for Metastatic Melanoma at the ASCO 2018 Annual Meeting

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the presentation of a Trials in Progress poster at the American Society of...

ONCS : 1.38 (-3.50%)
OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, has entered a clinical trial collaboration and supply agreement with Merck (known as MSD...

ONCS : 1.38 (-3.50%)
OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

SAN DIEGO , May 8, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, has entered a clinical trial collaboration...

ONCS : 1.38 (-3.50%)
Free Research Reports on These Biotech Stocks -- MannKind, Marinus Pharma, Mirati Therapeutics, and OncoSec Medical

If you want a free Stock Review on MNKD, MRNS, MRTX, and ONCS sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on MannKind Corp. (NASDAQ: MNKD), Marinus...

ONCS : 1.38 (-3.50%)
MRTX : 52.40 (+1.75%)
MNKD : 1.96 (+2.08%)
MRNS : 6.57 (-4.37%)
OncoSec to Present at Eighth Annual BioNJ BioPartnering Conference

SAN DIEGO , May 3, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor ...

ONCS : 1.38 (-3.50%)
OncoSec to Present at Eighth Annual BioNJ BioPartnering Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, Chief Executive Officer of OncoSec, will present...

ONCS : 1.38 (-3.50%)
OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, will present a trial-in-progress poster presentation from its global, multi-center, registration-directed...

ONCS : 1.38 (-3.50%)
OncoSec Provides Highlights from Research Reception at AACR Annual Meeting 2018

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today provided highlights from its Research Reception held on Sunday, April 15, 2018, during...

ONCS : 1.38 (-3.50%)
OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting

SAN DIEGO , April 3, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced it will host a Research...

ONCS : 1.38 (-3.50%)
OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced it will host a Research Reception at the 2018 American Association of Cancer...

ONCS : 1.38 (-3.50%)
Biotech Market Poised to Reach 2015 Highs

FN Media Group Presents Microcapspeculators.com News Commentary

PPCHD : 1.2000 (+20.00%)
INNT : 11.06 (+9.72%)
PPCB : 0.0619 (-3.28%)
ONCS : 1.38 (-3.50%)
GERN : 3.51 (-6.40%)
LPTX : 9.04 (+5.48%)
What's Happening with These Biotech Stocks? -- OncoSec Medical, OvaScience, Pacific Biosciences of California, and Pieris Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ONCS, OVAS, PACB, and PIRS which can be accessed for free by signing up to www.wallstequities.com/registration....

PACB : 3.92 (+0.26%)
ONCS : 1.38 (-3.50%)
OVAS : 0.98 (unch)
PIRS : 5.21 (-3.34%)
OncoSec Announces Strategic Relocation Of Office And Laboratories

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced a strategic relocation of its office and lab in San Diego that is expected...

ONCS : 1.38 (-3.50%)
OncoSec Announces Strategic Relocation Of Office And Laboratories

SAN DIEGO , March 20, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced a strategic relocation...

ONCS : 1.38 (-3.50%)
OncoSec To Present At The Oppenheimer's 28th Annual Healthcare Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, Chief Executive Officer of OncoSec, will present...

ONCS : 1.38 (-3.50%)
OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2018

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that clinical and immunological data from its OMS-I140 clinical trial of...

ONCS : 1.38 (-3.50%)
OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that its manuscript, "Improving therapeutic efficacy of IL-12 intratumoral...

ONCS : 1.38 (-3.50%)
This Morning's Technical Outlook on Biotech Stocks -- NewLink Genetics, OHR Pharma, Omeros, and OncoSec Medical

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on NLNK, OHRP, OMER, and ONCS which can be accessed for free by signing up to www.wallstequities.com/registration....

OHRP : 0.22 (unch)
ONCS : 1.38 (-3.50%)
OMER : 18.45 (-5.29%)
NLNK : 5.16 (-2.27%)
OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a biotechnology company focused on designing, developing and commercializing innovative immunotherapies and proprietary medical approaches to stimulate...

ONCS : 1.38 (-3.50%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.13 , FTNT -0.34 , CAKE +2.07 , PLT -0.37 , AEO +0.62
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures ended the Thursday session with most contracts 2 to 3 cents higher. This morning's USDA Export Sales report indicated that just 165,917 MT of old crop corn was sold in the week that ended June 14, well below estimates. That was lowest we...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar